4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:4SC AG (VSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10002
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including Resminostat, 4SC-202 and 4SC-208. The company’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG (VSC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
4SC AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
4SC Plans To Enters Into Co-Development Agreement For Resminostat 10
4SC Enters Into Co-Development Agreement With Crelux And Ribological 11
Licensing Agreements 12
Maruho Enters into Licensing Agreement with 4SC 12
Link Health Enters into Licensing Agreement with 4SC 13
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14
Equity Offering 15
4SC Raises USD46 Million in Rights Offering of Shares 15
4SC Raises USD32 Million in Rights Offering of Shares 16
Debt Offering 17
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17
Asset Transactions 18
Immunic Acquires Immunology Portfolio from 4SC 18
Acquisition 19
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19
4SC AG – Key Competitors 20
4SC AG – Key Employees 21
4SC AG – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Mar 21, 2018: 4SC announces results for financial year 2017 23
Aug 10, 2017: 4SC provides Q2 and 6M 2017 update 24
Product News 25
07/31/2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma 25
07/03/2018: Positive safety review of 4SC’s Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma 26
06/11/2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma 27
04/11/2017: New mechanistic insights into 4SC-202’s epigenetic mode of action 28
Other Significant Developments 29
Oct 25, 2018: 4SC provides Q3 business update and outlook 29
Oct 26, 2017: 4SC provides Q3 and 9M 2017 update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
4SC AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Deals By Therapy Area, 2012 to YTD 2018 8
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
4SC Plans To Enters Into Co-Development Agreement For Resminostat 10
4SC Enters Into Co-Development Agreement With Crelux And Ribological 11
Maruho Enters into Licensing Agreement with 4SC 12
Link Health Enters into Licensing Agreement with 4SC 13
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14
4SC Raises USD46 Million in Rights Offering of Shares 15
4SC Raises USD32 Million in Rights Offering of Shares 16
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17
Immunic Acquires Immunology Portfolio from 4SC 18
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19
4SC AG, Key Competitors 20
4SC AG, Key Employees 21

List of Figures
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abcam Plc (ABC):医療機器:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Lallemand Inc:企業の戦略・SWOT・財務情報
    Lallemand Inc - Strategy, SWOT and Corporate Finance Report Summary Lallemand Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • SRT Marine Systems plc (SRT):企業の財務・戦略的SWOT分析
    SRT Marine Systems plc (SRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Purity Wholesale Grocers Inc:企業の戦略的SWOT分析
    Purity Wholesale Grocers Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Quanta Computer Inc (2382):企業の財務・戦略的SWOT分析
    Quanta Computer Inc (2382) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Makedonijaturist AD Skopje:企業の戦略・SWOT・財務情報
    Makedonijaturist AD Skopje - Strategy, SWOT and Corporate Finance Report Summary Makedonijaturist AD Skopje - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Keio University-製薬・医療分野:企業M&A・提携分析
    Summary Keio University (Keio) is an educational institution that offers academic and research in various fields. The university provides primary and secondary education, graduate and undergraduate courses, and information technology courses. It offers academic courses in the field of economics, law …
  • Insys Therapeutics Inc (INSY):企業の財務・戦略的SWOT分析
    Insys Therapeutics Inc (INSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Energizer Holdings, Inc.:企業の戦略・SWOT・財務情報
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gastar Exploration Inc (GST):石油・ガス:M&Aディール及び事業提携情報
    Summary Gastar Exploration Inc (Gastar), formerly Gastar Exploration Ltd, is an energy company that offers exploration and development programs. The company explores, develops and produces natural gas, oil, and natural gas liquids. Its business activities include acquisition, identification, and exp …
  • Engro Corp Ltd (ENGRO):企業の財務・戦略的SWOT分析
    Engro Corp Ltd (ENGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • TOT Public Company Limited:企業の戦略的SWOT分析
    TOT Public Company Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • CS Wind Corp (112610):企業の財務・戦略的SWOT分析
    Summary CS Wind Corp (CS Wind) formerly Choong San Corp, is a global wind tower company that manufactures and distributes aluminum platforms used for wind power generation towers. The company’s products include transition piece, wind tower, tower internal parts, oil and gas pipes, and plant equipmen …
  • Pro Petroleum Inc:企業の戦略的SWOT分析
    Pro Petroleum Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ImmusanT Inc-製薬・医療分野:企業M&A・提携分析
    Summary ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are al …
  • Alarko Contracting Group:企業の戦略・SWOT・財務分析
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gordon Food Service Inc:企業の戦略的SWOT分析
    Gordon Food Service Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • E&A Limited:企業の戦略・SWOT・財務情報
    E&A Limited - Strategy, SWOT and Corporate Finance Report Summary E&A Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • New York Independent System Operator Inc:企業の戦略的SWOT分析
    New York Independent System Operator Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • DIA Imaging Analysis Ltd:医療機器:M&Aディール及び事業提携情報
    Summary DIA Imaging Analysis Ltd (DIA Imaging Analysis), formerly DiACardio Ltd is a provider of medical imaging solutions. The company’s products comprise LVivo SWM, LVivo EF, and LVivo Strain. Its LVivo SWM is a fully automated echo device or PACS systems. DiACardio’s LVivo platform comprises tool …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆